NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-09-29 18:19இன்று 15 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Hexagon Nutrition Completes Commercial Process Validation for Food Fortification Product 'VIT A+'
Hexagon Nutrition Limited and Particles for Humanity have successfully completed the commercial-scale process validation of PFH-VAP. The product, a stable formulation of Vitamin A Palmitate intended for large-scale food fortification, is proposed to be marketed internationally under the brand name 'VIT A+'. While this validates the manufacturing feasibility at scale, financial details, expected revenue, and capex were not disclosed in the filing. In the recent quarter ending June 2026, Hexagon reported revenue of Rs 104.31 crore and net profit of Rs 8.07 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுHexagon Nutrition validated the commercial manufacturing process of PFH-VAP, advancing it from development to preparation for commercial launch under the brand 'VIT A+'.
ஏன் இது முக்கியம்Proves manufacturing feasibility for a specialized food fortification product targeted at export markets, potentially expanding high-margin international revenues.
📅 குறுகிய காலம்Positive sentiment from technical and scale validation, though immediate financial impact is limited until commercial supply commences.
📈 நீண்ட காலம்Could open new international B2B and institutional revenue streams in the large-scale food fortification vertical if commercial adoption is successful.
⚠ அபாய எச்சரிக்கைகள்
Commercialization timeline and financial terms with partner Particles for Humanity not disclosed
Commercial uptake remains subject to international regulatory approvals and customer adoption
👀 கவனிக்க வேண்டியவை
Track the timeline for commercial rollout, regulatory approvals across target export markets, and eventual revenue contribution from international sales of VIT A+.
Hexagon Nutrition Chairman & ED Arun Kelkar Steps Down Effective September 28, 2026
Hexagon Nutrition Limited announced that its Chairman & Executive Director, Arun Purushottam Kelkar, has completed his tenure and stepped down effective September 28, 2026, at the close of office hours. Kelkar has led the company since its incorporation. The company reported revenue of Rs 104.31 crore and net profit of Rs 8.07 crore in the June 2026 quarter. Investors should monitor subsequent filings regarding leadership succession and board reconstitution.
உச்சம் நம்பிக்கை
என்ன மாறியதுArun Kelkar ceased to be Chairman & Executive Director upon completion of his tenure on September 28, 2026.
ஏன் இது முக்கியம்A transition in top leadership can influence future corporate strategy and operational direction, though this appears to be a scheduled tenure completion.
Date of Cessation: 28 செப்டம்பர் 2026Jun 2026 Revenue: Rs 104.306 கோடிJun 2026 PAT: Rs 8.073 கோடி
📅 குறுகிய காலம்Limited operational disruption expected as the exit is due to completion of term, though market will look for details on succession.
📈 நீண்ட காலம்The incoming Chairman/executive leadership will determine strategic priorities in the packaged foods and nutrition segments.
⚠ அபாய எச்சரிக்கைகள்
Leadership transition risk following departure of a founding leader
👀 கவனிக்க வேண்டியவை
Track board announcements regarding the appointment of a new Chairman or executive leadership changes and strategy continuity.
Hexagon Nutrition Seeks Legal Opinion After Promoters Abstain From Resolution Voting
Hexagon Nutrition Limited reported an update regarding voting outcomes on certain shareholder resolutions, disclosing that Promoter shareholders had abstained from voting. The company is actively seeking an independent legal opinion to decide on the appropriate course of action under applicable law. Further details on the specific resolutions or financial implications were not disclosed in the filing. Investors should note this development follows the company's June 2026 quarterly net profit of Rs 8.073 cr on revenue of Rs 104.306 cr.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுPromoters abstained from voting on specific corporate resolutions, prompting the company to seek external legal counsel.
ஏன் இது முக்கியம்Promoter abstention on key resolutions can signal governance complexities, related-party issues, or strategic disagreements, potentially delaying corporate approvals.
Announcement Date: செப்டம்பர் 23, 2026June 2026 Quarterly Revenue: Rs 104.306 கோடிJune 2026 Net Profit: Rs 8.073 கோடி
📅 குறுகிய காலம்Short-term uncertainty could persist until the company discloses the specific resolutions involved and the legal counsel's recommendation.
📈 நீண்ட காலம்Corporate governance clarity and promoter alignment will be key to avoiding operational or regulatory roadblocks in future resolutions.
⚠ அபாய எச்சரிக்கைகள்
Uncertainty around the validity or approval of the underlying resolutions
Potential governance or compliance issues leading to the legal review
👀 கவனிக்க வேண்டியவை
Track subsequent exchange filings regarding the legal opinion outcome and clarity on which shareholder resolutions were affected.
At Hexagon Nutrition's 33rd Annual General Meeting held on September 22, 2026, public shareholders pushed back on executive compensation and leadership continuity. Three special resolutions failed to pass: Resolution 7 (remuneration of Chairman Arun Kelkar), Resolution 8 (remuneration of MD Vikram Kelkar), and Resolution 11 (re-appointment of Arun Kelkar as Chairman & Executive Director), all receiving 60.86% votes against from voting members. However, routine items including adoption of FY26 financial statements, dividend declaration, and revision of Joint MD Dr. Nikhil Kelkar's remuneration were approved.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders formally rejected the re-appointment and remuneration of Chairman Arun Kelkar and the remuneration hike for MD Vikram Kelkar.
ஏன் இது முக்கியம்The rejection of key promoter executive resolutions signals significant institutional or public shareholder dissent on corporate governance and executive pay structure.
Votes against Chairman re-appointment: 60.86%Votes against MD remuneration revision: 60.86%Total voting shares polled on Resolution 11: 4055160Total shareholders on record date (15-09-2026): 22335
📅 குறுகிய காலம்Heightened scrutiny on the board's corporate governance stance and potential overhang until the leadership status of Chairman Arun Kelkar is resolved.
📈 நீண்ட காலம்Strong pushback from non-promoter shareholders typically leads to better-aligned executive compensation and improved board independence over time.
Leadership uncertainty following the failed re-appointment of the Chairman
👀 கவனிக்க வேண்டியவை
Track subsequent board notifications regarding governance adjustments, executive leadership succession, or revised compensation proposals following the rejection of the Chairman's re-appointment.
Q1 FY27 Call Transcript: Revenue Up 43.2% to ₹104.3 Cr; MRP Hiked 10-15% to Offset Margin Headwinds
Hexagon Nutrition released the transcript of its Q1 FY27 earnings conference call following its recent June 2026 listing. Consolidated revenue grew 43.2% YoY to ₹104.3 crore (up from ₹72.9 crore), with PAT rising 25.1% YoY to ₹8.1 crore. EBITDA increased at a slower pace of 17.3% YoY to ₹11.8 crore due to raw material inflation and elevated freight costs from geopolitical tensions in West Asia. Segment growth was led by Premix (+55% YoY), ESG (+42% YoY), and Branded nutrition (+22% YoY). To protect profitability, the company implemented a 10% to 15% price hike and expanded its sales field force by over 50% YoY.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the full transcript of the Q1 FY27 earnings conference call held on August 14, 2026.
ஏன் இது முக்கியம்Provides detail on how management plans to protect EBITDA margins against freight/raw material pressures through price hikes and sales force expansion.
📅 குறுகிய காலம்Earnings details are already in the market; short-term attention will focus on margin stabilization post-price hikes.
📈 நீண்ட காலம்Broadening product penetration in clinical nutrition and export diversification across 70+ countries support long-term scalability.
⚠ அபாய எச்சரிக்கைகள்
Gross margin compression from raw material price volatility
Geopolitical freight cost pressures linked to West Asia
Lag in sales productivity from the >50% surge in field force headcount
👀 கவனிக்க வேண்டியவை
Track whether the 10-15% price hikes successfully restore gross margins in Q2-Q3 FY27 and assess productivity gains from the expanded field force.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Hexagon Nutrition reported Q1 FY27 revenue of ₹104.3 cr with an EBITDA margin of 11.3% and PAT of ₹8.1 cr. Following its June 2026 listing, the company is focusing on its B2C clinical nutrition segment (Pentasure) and its B2B2C premix business. The company operates four manufacturing plants across India and Uzbekistan, though capacity utilization remains low in certain segments like Uzbekistan (3.3%). Management is targeting the ₹1.3 trillion Indian nutrition market, which is projected to grow at a 13% CAGR through 2030.
உச்சம் நம்பிக்கை
என்ன மாறியதுThis is the first comprehensive investor presentation following the company's June 2026 listing, detailing its Q1 FY27 financial performance and business model.
ஏன் இது முக்கியம்It provides transparency into the company's revenue mix and operational efficiency across its clinical, wellness, and humanitarian nutrition segments.
📅 குறுகிய காலம்The stock may react to the 11.3% EBITDA margin as investors benchmark this newly listed player against established FMCG and nutrition peers.
📈 நீண்ட காலம்Structural growth depends on the company's ability to scale its B2C brands (Pentasure, Pediagold) and capitalize on the 12.1% projected CAGR in the clinical nutrition market.
⚠ அபாய எச்சரிக்கைகள்
Low capacity utilization in Uzbekistan (3.3%) and Thoothukudi (18.9%)
High dependence on hospital and dietitian recommendations for B2C sales
👀 கவனிக்க வேண்டியவை
Monitor capacity utilization improvements at the Thoothukudi (18.9%) and Uzbekistan (3.3%) plants, as higher throughput is essential for margin expansion.
43.2% Revenue Growth in Q1 FY27; PAT up 25.1% to ₹8.1 Cr in First Post-IPO Results
Hexagon Nutrition reported a strong 43.2% YoY revenue growth to ₹104.3 crore for Q1 FY27, marking its first quarterly disclosure since its June 2026 IPO. While the top-line showed robust momentum, EBITDA margins contracted by 250 basis points to 11.3% compared to 13.8% in the previous year's quarter. Consequently, EBITDA growth of 17.3% lagged behind revenue growth. Profit After Tax (PAT) increased by 25.1% to ₹8.1 crore, supported by the company's diversified presence across 70+ countries.
உச்சம் நம்பிக்கை
என்ன மாறியதுThis is the first financial performance report issued by Hexagon Nutrition as a publicly listed entity following its IPO in June 2026.
ஏன் இது முக்கியம்It establishes a performance baseline for the company as a listed entity, demonstrating strong demand for its micronutrient and clinical nutrition products despite margin pressures.
📅 குறுகிய காலம்The strong top-line growth is likely to be viewed positively by the market, though the 250 bps margin contraction may lead to some caution regarding cost management.
📈 நீண்ட காலம்The company is positioned in the high-growth nutrition and fortification segment; long-term value depends on scaling its international presence and maintaining operational efficiency.
⚠ அபாய எச்சரிக்கைகள்
EBITDA margin compression of 250 bps YoY
Potential raw material price volatility affecting gross margins
Execution risks in diverse international markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to stabilize EBITDA margins back toward the FY26 level of 13.8% and track the scaling of international operations which currently span 70+ countries.
Hexagon Nutrition Recommends ₹0.30 Dividend and Re-appoints Chairman
Hexagon Nutrition's board has recommended a final dividend of ₹0.30 per equity share (30% of face value) for FY26, with a record date of September 15, 2026. The company approved its Q1 FY27 financial results and scheduled its 33rd Annual General Meeting for September 22, 2026. Key management decisions include the re-appointment of Arun Purushottam Kelkar as Chairman and the appointment of Raghunath Sawant as an Additional Executive Director. The board also approved revisions to the remuneration of promoter-directors, subject to shareholder approval.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has declared its final dividend for the previous fiscal year, updated its board composition with a new executive director, and initiated the process for re-appointing its Chairman.
ஏன் இது முக்கியம்The announcement confirms management continuity and provides a clear timeline for dividend payouts, which is a key return metric for shareholders in the packaged foods sector.
Final Dividend: ₹0.30 per shareFace Value: ₹1 per shareரெக்கார்ட் தேதி: செப்டம்பர் 15, 2026AGM Date: செப்டம்பர் 22, 2026
📅 குறுகிய காலம்The stock may see some interest leading up to the dividend record date of September 15, 2026.
📈 நீண்ட காலம்Leadership continuity is maintained through the re-appointment of the Chairman; however, the impact of increased director remuneration on net margins should be monitored.
⚠ அபாய எச்சரிக்கைகள்
Remuneration revisions for three promoter-directors (Kelkar family) may impact profitability if not aligned with growth
👀 கவனிக்க வேண்டியவை
Investors should review the Q1 FY27 financial performance once the full results are published and monitor the details of the proposed remuneration revisions for promoter-directors in the upcoming AGM notice.
Hexagon Nutrition has recommended a final dividend of ₹0.30 per share (30% of face value) for FY26, with a record date of September 15, 2026. The board approved Q1 FY27 financial results and scheduled the 33rd AGM for September 22, 2026. Key leadership decisions include the re-appointment of Chairman Arun Kelkar for a 5-year term and the appointment of Raghunath Sawant as an Additional Executive Director. The company also dissolved its IPO committee following successful completion of its listing process.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned out of its IPO phase by dissolving the IPO committee and has established its dividend and leadership roadmap for the next five years.
ஏன் இது முக்கியம்The dividend recommendation signals a commitment to shareholder returns, while the 5-year re-appointment of the Chairman ensures leadership stability for the newly listed entity.
Final Dividend: ₹0.30 per shareFace Value: ₹1ரெக்கார்ட் தேதி: செப்டம்பர் 15, 2026AGM Date: செப்டம்பர் 22, 2026Chairman Re-appointment Term: 5 years
📅 குறுகிய காலம்The stock may see interest leading up to the dividend record date in mid-September; however, the primary driver will be the Q1 FY27 earnings performance.
📈 நீண்ட காலம்Leadership continuity and the cleanup of the Articles of Association (removing VC-specific clauses) indicate a maturing corporate governance structure post-listing.
⚠ அபாய எச்சரிக்கைகள்
Revision in promoter-director remuneration requires shareholder approval
Removal of specific clauses in Articles of Association
👀 கவனிக்க வேண்டியவை
Investors should review the detailed Q1 FY27 financial results and monitor the shareholder vote on the proposed revision of Director remuneration at the upcoming AGM.
₹0.30 Final Dividend Recommended; Record Date Fixed for Sept 15, 2026
Hexagon Nutrition has recommended a final dividend of ₹0.30 per share (30% of face value) for FY26, with the record date set for September 15, 2026. The board also approved the unaudited financial results for Q1 FY27 and scheduled the 33rd AGM for September 22, 2026. Key management updates include the re-appointment of Chairman Arun Kelkar for a 5-year term and the appointment of Raghunath Sawant as an Additional Executive Director. Additionally, the company is amending its Articles of Association to remove references to Malani Ventures and has dissolved its IPO committee following the successful listing.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its first post-IPO dividend, updated its leadership structure, and initiated a cleanup of its Articles of Association by removing legacy investor references.
ஏன் இது முக்கியம்The dividend recommendation signals management's intent to share profits with shareholders, while the 5-year re-appointment of the Chairman ensures leadership continuity in the post-listing phase.
Final Dividend: ₹0.30 per shareFace Value: ₹1ரெக்கார்ட் தேதி: செப்டம்பர் 15, 2026AGM Date: செப்டம்பர் 22, 2026Chairman Tenure: 5 years
📅 குறுகிய காலம்The stock may see neutral to positive movement as investors react to the dividend announcement and the Q1 FY27 earnings performance.
📈 நீண்ட காலம்The dissolution of the IPO committee and removal of legacy clauses in the AoA indicate the company is maturing into its status as a public entity with stable promoter leadership.
⚠ அபாய எச்சரிக்கைகள்
Revision in promoter-director remuneration (subject to shareholder approval)
👀 கவனிக்க வேண்டியவை
Investors should review the Q1 FY27 financial results once fully published to assess growth trends and monitor the AGM for approval of the dividend and revised director remuneration.
₹0.30 Dividend Recommended; Hexagon Nutrition Appoints New Director and Dissolves IPO Committee
Hexagon Nutrition's board has recommended a final dividend of ₹0.30 per share (30% of face value) for FY26, with a record date of September 15, 2026. The company is transitioning to a post-IPO structure, evidenced by the dissolution of its IPO Committee and the removal of specific investor rights (Malani Ventures) from its Articles of Association. Management changes include the appointment of Raghunath Sawant as Additional Executive Director and a proposed revision in remuneration for the promoter-directors. The 33rd Annual General Meeting is scheduled for September 22, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its dividend payout timeline, updated its board composition, and cleaned up its Articles of Association by removing pre-IPO investor references.
ஏன் இது முக்கியம்These actions signal the company's normalization as a listed entity and provide a direct cash return to shareholders, while management changes indicate a shift in governance structure.
Final Dividend: ₹0.30 per shareFace Value: ₹1ரெக்கார்ட் தேதி: செப்டம்பர் 15, 2026AGM Date: செப்டம்பர் 22, 2026Director Appointment Term: 5 years
📅 குறுகிய காலம்The stock may experience minor price adjustments around the dividend record date of September 15, 2026.
📈 நீண்ட காலம்Limited structural impact; the changes reflect standard corporate governance and administrative updates for a newly listed company.
⚠ அபாய எச்சரிக்கைகள்
Revision in promoter-director remuneration requires shareholder scrutiny regarding performance alignment.
👀 கவனிக்க வேண்டியவை
Investors should review the Q1 FY27 financial results once published in full and monitor the proposed increase in promoter-director remuneration at the upcoming AGM on September 22, 2026.
₹66 Cr Bank Facilities Assigned 'CARE A-; Stable' Rating; Agency Changed to CARE
Hexagon Nutrition Limited has transitioned its credit rating mandate from ICRA Limited to CARE Ratings Limited. CARE has assigned a 'CARE A-; Stable' rating for ₹23 crore in long-term bank facilities and a dual 'CARE A-; Stable / CARE A2+' rating for ₹43 crore in long/short-term facilities. The total rated debt of ₹66 crore includes ₹18.03 crore in proposed term loans, indicating potential future borrowing. This rating reflects the agency's independent assessment of the company's financial and operational profile as of late July 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has replaced ICRA Limited with CARE Ratings Limited as its credit rating agency and received fresh ratings for its bank facilities.
ஏன் இது முக்கியம்A credit rating of 'A-' signifies a low risk of default and provides transparency regarding the company's ability to service its ₹66 crore debt, which is critical for maintaining banking relationships and managing interest costs.
Total Rated Facilities: ₹66.00 கோடிLong Term Rating: CARE A-; StableShort Term Rating: CARE A2+Proposed Term Loans: ₹18.03 கோடிRating Date: ஜூலை 29, 2026
📅 குறுகிய காலம்The announcement is administrative and likely to have a neutral impact on the stock price in the immediate term.
📈 நீண்ட காலம்The 'Stable' outlook suggests the company is expected to maintain its financial profile over the next year; structural significance is limited unless the proposed loans lead to major capex.
⚠ அபாய எச்சரிக்கைகள்
Potential volatility if rating-related trigger clauses are introduced in bank facility terms.
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization of the ₹18.03 crore proposed term loans to see if they are directed toward capacity expansion. The 'A-' rating indicates a stable credit profile, but any future change in this rating could impact the company's borrowing costs.
Hexagon Nutrition conducted its maiden earnings call post-listing, highlighting a diversified portfolio across clinical nutrition and food fortification. Trade receivables increased to ₹82 crore in FY26 from ₹60 crore in FY25, attributed to large ESG and domestic premix orders dispatched in the final quarters. Management expressed confidence in maintaining a historical growth trajectory of 15-20% for FY27, despite geopolitical tensions in West Asia. The company is focusing on expanding its brands PediaGold and Obesigo into Tier 2 and Tier 3 cities to compete with global players.
உச்சம் நம்பிக்கை
என்ன மாறியதுThis filing provides the first detailed management commentary post-listing, clarifying segment-wise performance and addressing concerns regarding rising receivables.
ஏன் இது முக்கியம்It establishes the company's growth guidance (15-20%) and reveals the management's strategy to penetrate deeper into the Indian clinical nutrition market beyond Tier 1 cities.
📅 குறுகிய காலம்The stock may see neutral to slightly cautious sentiment as investors digest the increase in trade receivables despite the positive growth outlook.
📈 நீண்ட காலம்The company is positioned in a structural growth industry (preventive healthcare) with a focus on high-margin clinical nutrition, which could drive value if execution in Tier 2/3 cities succeeds.
⚠ அபாய எச்சரிக்கைகள்
Elongated receivable cycle due to large ESG and domestic orders
High competition in clinical nutrition from global majors like Abbott
👀 கவனிக்க வேண்டியவை
Monitor the normalization of trade receivables in the H1FY27 results to ensure working capital cycles are stabilizing as management suggested.
Hexagon Nutrition Discloses ₹13.31 Cr Net Liability in Overseas Subsidiaries
Hexagon Nutrition has issued a comprehensive clarification to its Prospectus, correcting several administrative and financial disclosures. The most significant update reveals that its South African and Uzbekistan subsidiaries carry a combined net liability of ₹133.15 million as of December 31, 2025, due to historical losses. While these units turned a profit of ₹20.94 million in the current period, they remain dependent on an unconditional financial guarantee from the parent company to continue operations. Additionally, the company redefined its Chief Operating Decision Maker (CODM) from the CFO to the Managing Director.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company revised its Prospectus to include specific 'going concern' justifications for overseas units and corrected various auditor and management designations.
ஏன் இது முக்கியம்This filing provides a more transparent view of the financial risks in international operations, specifically the reliance of certain subsidiaries on parent company funding to meet liabilities.
Net liability (Overseas units): ₹133.15 millionCurrent period profit (Overseas units): ₹20.94 millionReporting date for liabilities: டிசம்பர் 31, 2025Number of subsidiaries clarified: 6
📅 குறுகிய காலம்The market may react cautiously to the formal disclosure of net liabilities and the material uncertainty regarding future cash flows in overseas markets.
📈 நீண்ட காலம்The structural health of the company depends on these international units becoming self-sustaining and reducing their reliance on the parent company's financial guarantees.
⚠ அபாய எச்சரிக்கைகள்
Material uncertainty regarding future cash flows in regional markets
Reliance on parent company for unconditional financial support
Historical accumulated losses in overseas subsidiaries
👀 கவனிக்க வேண்டியவை
Investors should monitor the quarterly performance of the South African and Uzbekistan subsidiaries to verify if the recent ₹20.94 million profit is a sustainable trend or a one-off recovery.
₹3,826 Mn FY26 Revenue: Hexagon Nutrition Reports 13.8% EBITDA Margin and 20.9% ROCE
Hexagon Nutrition Limited reported a strong FY26 performance with revenue reaching ₹3,826 Mn, reflecting a 13.4% CAGR since FY24. Profitability showed significant improvement, with EBITDA margins expanding from 6.2% in FY24 to 13.82% in FY26, and PAT margins reaching 9.9%. The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.13x and a high ROCE of 20.9%. Exports remain a dominant revenue driver, contributing 57% (₹2,163 Mn) of total sales across 80+ countries.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its first comprehensive investor presentation post-listing, detailing full-year FY26 financial performance and operational metrics.
ஏன் இது முக்கியம்The results demonstrate significant operating leverage, with margins expanding rapidly as the company scales its integrated nutrition platform across 80+ countries while remaining nearly debt-free.
📅 குறுகிய காலம்The stock may see positive sentiment as the market reacts to the strong margin expansion and high ROCE figures disclosed in this post-listing presentation.
📈 நீண்ட காலம்The company is well-positioned in the high-growth nutraceutical sector with a diversified portfolio and a strong global footprint, suggesting sustainable long-term growth potential.
⚠ அபாய எச்சரிக்கைகள்
High dependence on export markets (57% of revenue)
Raw material price volatility (24% of materials are imported)
👀 கவனிக்க வேண்டியவை
Investors should monitor the growth of the B2C clinical nutrition segment (Pentasure brand) and the operational ramp-up of the Uzbekistan manufacturing facility for international market penetration.
1 Executive Director Resigns: Subhash Purushottam Kelkar departs Hexagon Nutrition
Hexagon Nutrition Limited has announced the resignation of Mr. Subhash Purushottam Kelkar from his position as Executive Director. The resignation became effective on July 6, 2026. As an Executive Director, Mr. Kelkar was part of the company's senior leadership team. The company has not disclosed the reason for his departure or a successor in this specific filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. Subhash Purushottam Kelkar has stepped down from his role as Executive Director of Hexagon Nutrition Limited.
ஏன் இது முக்கியம்The resignation of an Executive Director impacts the board's composition and potentially the oversight of specific business functions.
Effective Date: ஜூலை 6, 2026Filing Date: ஜூலை 7, 2026
📅 குறுகிய காலம்The stock may see neutral movement as the market awaits details on the successor and the impact on operations.
📈 நீண்ட காலம்Limited structural significance unless this marks a broader shift in the company's leadership strategy or governance.
👀 கவனிக்க வேண்டியவை
Monitor future filings for the appointment of a new Executive Director to understand the company's leadership transition plan.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
